Vericel (NASDAQ:VCEL) Sees Large Volume Increase

Share on StockTwits

Shares of Vericel Corp (NASDAQ:VCEL) saw strong trading volume on Monday . 710,426 shares traded hands during trading, an increase of 29% from the previous session’s volume of 550,490 shares.The stock last traded at $18.94 and had previously closed at $18.66.

VCEL has been the subject of several research reports. BidaskClub upgraded shares of Vericel from a “hold” rating to a “buy” rating in a research report on Tuesday, October 29th. ValuEngine upgraded shares of Vericel from a “hold” rating to a “buy” rating in a research note on Monday, November 25th. Needham & Company LLC reiterated a “hold” rating on shares of Vericel in a research note on Tuesday, November 5th. Zacks Investment Research reissued a “buy” rating and set a $16.00 target price on shares of Vericel in a research report on Saturday, October 12th. Finally, BTIG Research set a $24.00 price target on shares of Vericel and gave the stock a “buy” rating in a research note on Monday, August 12th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $21.78.

The company has a debt-to-equity ratio of 0.26, a quick ratio of 6.48 and a current ratio of 6.93. The company has a market cap of $836.15 million, a P/E ratio of -133.14 and a beta of 2.72. The firm has a 50 day moving average price of $17.39 and a two-hundred day moving average price of $17.04.

Vericel (NASDAQ:VCEL) last announced its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported $0.07 earnings per share for the quarter, topping the consensus estimate of ($0.02) by $0.09. Vericel had a positive return on equity of 3.66% and a negative net margin of 12.68%. The company had revenue of $30.50 million during the quarter, compared to analyst estimates of $26.84 million. During the same quarter last year, the firm posted ($0.02) EPS. The firm’s revenue for the quarter was up 35.6% on a year-over-year basis. On average, sell-side analysts predict that Vericel Corp will post 0.16 EPS for the current fiscal year.

In other news, COO Michael Halpin sold 15,047 shares of the firm’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $18.53, for a total value of $278,820.91. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Dominick Colangelo sold 58,125 shares of the firm’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $14.88, for a total value of $864,900.00. The disclosure for this sale can be found here. 4.50% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. lifted its holdings in Vericel by 2.4% during the 2nd quarter. BlackRock Inc. now owns 3,168,165 shares of the biotechnology company’s stock worth $59,846,000 after purchasing an additional 73,814 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Vericel by 2.6% in the second quarter. Vanguard Group Inc. now owns 2,607,132 shares of the biotechnology company’s stock valued at $49,249,000 after acquiring an additional 66,650 shares during the period. Waddell & Reed Financial Inc. bought a new position in shares of Vericel in the second quarter valued at approximately $38,159,000. Nuveen Asset Management LLC purchased a new position in Vericel during the second quarter valued at approximately $16,152,000. Finally, Redwood Investments LLC purchased a new position in Vericel during the second quarter valued at approximately $15,775,000. Institutional investors own 86.86% of the company’s stock.

Vericel Company Profile (NASDAQ:VCEL)

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns.

Recommended Story: Marijuana Stocks

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.